Effect of selective serotonin re-uptake inhibitors (SSRIs) on functional outcome in patients with acute ischemic stroke treated with tPA

[1]  M. Mattson,et al.  Glutamate and Neurotrophic Factors in Neuronal Plasticity and Disease , 2008, Annals of the New York Academy of Sciences.

[2]  J. De Keyser,et al.  Therapeutic Potential of Fluoxetine in Neurological Disorders , 2008, CNS neuroscience & therapeutics.

[3]  A. Hazell.  Excitotoxic mechanisms in stroke: An update of concepts and treatment strategies , 2007, Neurochemistry International.

[4]  M. Irwin,et al.  Depressive disorders and immunity: 20 years of progress and discovery , 2007, Brain, Behavior, and Immunity.

[5]  G. Luijckx,et al.  Safety of routine IV thrombolysis between 3 and 4.5 h after ischemic stroke , 2007, Journal of the Neurological Sciences.

[6]  Teruo Hayashi,et al.  Chronic Antidepressants Potentiate via Sigma-1 Receptors the Brain-derived Neurotrophic Factor-induced Signaling for Glutamate Release* , 2006, Journal of Biological Chemistry.

[7]  R. Robinson,et al.  The Effect of Early versus Late Antidepressant Treatment on Physical Impairment Associated with Poststroke Depression: Is There a Time-Related Therapeutic Window? , 2003, The Journal of nervous and mental disease.

[8]  R. Robinson,et al.  Mortality and poststroke depression: a placebo-controlled trial of antidepressants. , 2003, The American journal of psychiatry.

[9]  T. Zetterström,et al.  Bi-phasic change in BDNF gene expression following antidepressant drug treatment , 2003, Neuropharmacology.

[10]  E. Castrén,et al.  Activation of the TrkB Neurotrophin Receptor Is Induced by Antidepressant Drugs and Is Required for Antidepressant-Induced Behavioral Effects , 2003, The Journal of Neuroscience.

[11]  R. Robinson,et al.  Preventing Poststroke Depression: A 12-Week Double-Blind Randomized Treatment Trial and 21-Month Follow-up , 2002, The Journal of nervous and mental disease.

[12]  J. Mulder,et al.  Oral post-lesion administration of 5-HT1A receptor agonist repinotan hydrochloride (BAY x 3702) attenuates NMDA-induced delayed neuronal death in rat magnocellular nucleus basalis , 2001, Neuroscience.

[13]  F. Chollet,et al.  Fluoxetine modulates motor performance and cerebral activation of patients recovering from stroke , 2001, Annals of neurology.

[14]  R. Robinson,et al.  Treatment of cognitive impairment after poststroke depression : a double-blind treatment trial. , 2000, Stroke.

[15]  J. Keyser,et al.  Clinical trials with neuroprotective drugs in acute ischaemic stroke: are we doing the right thing? , 1999, Trends in Neurosciences.

[16]  P. Tonin,et al.  Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy. , 1996, Stroke.

[17]  J. Bamford,et al.  Classification and natural history of clinically identifiable subtypes of cerebral infarction , 1991, The Lancet.

[18]  R G Robinson,et al.  The impact of poststroke depression on recovery in activities of daily living over a 2-year follow-up. , 1990, Archives of neurology.

[19]  E. Huang,et al.  Neurotrophins: roles in neuronal development and function. , 2001, Annual review of neuroscience.

[20]  Mu-ming Poo,et al.  Neurotrophins as synaptic modulators , 2001, Nature Reviews Neuroscience.

[21]  L C Katz,et al.  Neurotrophins and synaptic plasticity. , 1999, Annual review of neuroscience.

[22]  S. Paradiso,et al.  Effect of antidepressant therapy on executive function after stroke * , 2022 .